Refine by
Patient Testing Articles & Analysis
245 news found
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). ...
ByTempus
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to ...
ByTempus
These services are designed to help medical device manufacturers meet regulatory requirements and ensure the safety and effectiveness of their products. Medical device safety testing is a critical component of the product development process, ensuring that medical devices meet regulatory requirements and are safe for use by patients. ...
These conditions pose significant challenges to patients' health and well-being. To delve into these diseases, rodents are commonly employed as research subjects in cognitive-behavioral testing. ...
We are thrilled to announce that Vantage, has successfully passed NHS England’s rigorous LFPSE (Learning from Patient Safety Events) compliance testing and are officially recognised as an accredited LFPSE supplier. This accreditation is a testament to our commitment to enhancing patient safety in healthcare organisations across the nation. ...
Therefore, it is important to assess the patient's physical condition and possible risk of complications prior to treatment. ...
A third site is an academic medical center and is recognized as one of the top heart failure centers in the U.S. with more than 800 physicians in 200 specialties serving patients in Virginia. The site in Mississippi is a community-based facility providing care to patients in five counties in northeast Mississippi and three counties in southern Tennessee, while ...
Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care. In both study arms, patients had BVA testing within a day of admission and one day prior to discharge, along with physician assessment for congestion. ...
Universal volume-directed interventions (i.e. diuretics) in HF patients with high pressures might not be appropriate and should be ...
In both study arms, patients had BVA testing within a day of admission and one day prior to discharge, along with physician assessment for congestion. ...
Before joining Daxor, Linda has held several senior leadership roles with major medical device companies including OsteoCentric Technologies and Integra LifeSciences where she oversaw multiple product launches through the entire product development process including software and hardware design, testing, regulatory clearance, initial build and launch. She earned her Bachelor of ...
We advise patients to get tested for ESR1 mutations at progression in their metastatic treatment, so that their healthcare team can identify the right treatment options for their ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, and patients. About Daxor Corporation Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood ...
In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that osteoporosis will be responsible for approximately three million fractures and $25.3 billion in costs annually.” Sadly, most patients are not aware of having the condition before suffering from a ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available ...
The company applies a machine learning -driven approach to pre-flight medical advancements without extra trials or animal testing, allowing more patients to receive proper care and accelerating its partners' research findings. ...
(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. ...
About Daxor: Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition ...
About Daxor: Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition ...